Keyphrases
Multiple Myeloma
62%
Multiple Myeloma Patients
47%
Relapsed or Refractory multiple Myeloma
37%
Bortezomib
27%
Newly Diagnosed multiple Myeloma
25%
Daratumumab
24%
Lenalidomide
17%
Chimeric Antigen Receptor T Cells (CAR-T)
17%
Overall Survival
16%
Myeloma
15%
B-cell Maturation Antigen
15%
Confidence Interval
14%
Clinical Outcomes
13%
Multicenter Retrospective Study
13%
Progression-free Survival
12%
Protease Inhibitors
11%
COVID-19
11%
Smoldering multiple Myeloma
11%
Israeli
11%
High Risk
10%
Overall Response Rate
10%
Immunomodulatory Drugs (IMiDs)
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Clinical Characteristics
9%
Clinical Data
9%
Brexucabtagene Autoleucel
9%
Novel Agents
9%
Transplant Eligibility
9%
Median Progression-free Survival
8%
Median Overall Survival
8%
Adverse Events
8%
Multivariate Analysis
8%
BNT162b2
8%
Free Light Chains
8%
BNT162b2 Vaccine
7%
Light Chain Amyloidosis
7%
Minimal Residual Disease
7%
Phase II Study
7%
Anti-B
6%
Tolerability
6%
Correspondence Analysis
6%
Belantamab Mafodotin
6%
COVID-19 Vaccine
6%
Cord Blood Transplantation
6%
Worse Outcome
6%
Oncology Patients
6%
Cilta-cel
6%
Intermediate Risk
6%
Cytokine Release Syndrome
6%
Response Rate
5%
Medicine and Dentistry
Multiple Myeloma
100%
Diseases
22%
Myeloma
20%
Retrospective Study
19%
B Cell Maturation Antigen
18%
Bortezomib
18%
Lenalidomide
18%
Progression Free Survival
17%
Chimeric Antigen Receptor T-Cell
14%
Overall Survival
13%
Proteasome Inhibitor
13%
Clinical Trial
13%
Light Chain
13%
COVID-19
11%
Dexamethasone
11%
Daratumumab
10%
Plasmacytoma
10%
Messenger RNA
10%
Smouldering Myeloma
7%
Minimal Residual Disease
7%
Amyloidosis
7%
Multivariate Analysis
7%
Cohort Analysis
7%
Humoral Immunity
7%
Infection
7%
Cell Transplantation
7%
Hematopoietic Cell
7%
Non-Hodgkin Lymphoma
6%
Clinical Study
6%
Adverse Event
6%
Cytokine Release Syndrome
6%
Cytokine
5%
Chimeric Antigen Receptor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
91%
B Cell Maturation Antigen
22%
Progression Free Survival
21%
Diseases
21%
Daratumumab
21%
Bortezomib
18%
Overall Survival
17%
Clinical Trial
17%
Infection
14%
Lenalidomide
14%
Retrospective Study
11%
Chimeric Antigen Receptor
11%
Amyloidosis
10%
Adverse Event
10%
Proteasome Inhibitor
8%
Dexamethasone
8%
Myeloma
8%
Cytokine Release Syndrome
7%
Smoldering Multiple Myeloma
7%
AL Amyloidosis
7%
Cohort Study
6%
Belantamab Mafodotin
6%
Nonhodgkin Lymphoma
6%
Clinical Study
6%
Messenger RNA
6%
Tolerability
6%
Minimal Residual Disease
5%
Cytokine
5%